alexa Modern Markers Of Diabetic Cardiomyopathy
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Diabetes & Metabolism
November 03-05, 2014 Embassy Suites Las Vegas, USA

Andrey Aleksandrov
Posters: J Diabetes Metab
DOI: 10.4172/2155-6156.S1.027
Introduction: Currently, there is a marked increase in the incidence of diabetes and the severity of its cardiovascular complications is largely determined by a specific change of myocardium - diabetic cardiomyopathy. Search for new biomarkers of diabetic cardiomyopathy and identify major pathogenetic mechanisms of development determines the choice of therapy and prognosis. Aim: To evaluate the effect of resistin on the formation of structural and functional parameters of the left ventricle (LV) of the heart in patients with diabetes mellitus (DM) type 2 with preserved and reduced ejection fraction. In patients with type 2 diabetes to compare resistin and MMP-9 concentrations in the blood that control the exchange of extracellular matrix Materials and Methods: The study included 90 patients with type 2 diabetes with CHF II-III NYHA class, the average age was 62 years. 60 people of them had a left ventricular ejection fraction (LVEF) over 55% and 30 people - less than 45%. Patients underwent echocardiography, Holter ECG monitoring, determination of the concentration of resistin and MMP-9 in the blood. Results: According to echocardiography in 60 patients with preserved EF concentric left ventricular hypertrophy (LVH) was diagnosed in 29 people, eccentric LVH - in 12 people. A positive correlation was found between resistin level and end-diastolic dimension LV (r=0.43, p=0.020) in the group with concentric LVH. Negative correlation was found between resistin level and end-diastolic dimension LV (r = -0.61 p=0.000). In patients with type 2 diabetes with concentric left ventricular hypertrophy was a statistically significant increase in the number of supraventricular extrasystoles compared with a group of patients with eccentric LVH (202 [0; 374] vs 20 [0; 159], p=0.025). Moreover, in patients with concentric LVH was found a positive correlation between resistin level and supraventricular extrasystoles quantity (r=0.34; p=0.033). In patients with reduced LVEF higher level of MMP-9 and resistin fell on a group of patients with the lowest LVEF. In the analysis, in patients with type 2 diabetes with reduced LVEF was found significant correlation relationship between resistin and MMP-9 level, which is close to statistical significance (r=0,45, p=0.057). Conclusions: Physiological secretion of resistin in patients with type 2 diabetes with myocardial hypertrophy can be seen as an adaptation mechanism aimed at reducing the rate of rise of heart failure. In patients with type 2 diabetes with concentric left ventricular hypertrophy, increased resistin secretion is a risk factor for supraventricular arrhythmias. Increased MMP-9 level in the blood of patients with type 2 diabetes with evidence of LV dilatation of the heart and/or myocardial hypertrophy contributes to increasing severity of contractile dysfunction of the left ventricular myocardium.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version